Uday Baldota - Taro Pharmaceutical Chief Executive Officer, Director
CEO
Mr. Uday Baldota is Chief Executive Officer, Director of the Company. Mr. Baldota became a member of the Taro Board in December 2016 and assumed the role of Chief Executive Officer in August 2017. He continues as a member of the global Core Management Team of Sun Pharma. Mr. Baldota was formerly Executive Vice President Chief Financial Officer of Sun Pharma. He led their global Finance function from June 2012 and was designated as the Chief Financial Officer in August 2014. From June 2005 to May 2012, Mr. Baldota served in various leadership positions as a Vice President and later Senior Vice President reporting to the Chairman and Managing Director of Sun Pharma. Mr. Baldotas areas of responsibility over his tenure at Sun Pharma have included accounting, MA, business finance, tax, treasury, insurance, controllership, legal, corporate secretarial, corporate communication and internal audit. Mr. Baldota was the Vice President Purchasing of Lafarge India Limited from March 2003 to June 2005 and served as its Head of Information Technology from November 1999 to March 2003. Prior to that, Mr. Baldota served in various IT and marketing roles with Sun Pharma between May 1995 and November 1999 since 2017.
| Age | 54 |
| Tenure | 8 years |
| Phone | 972 4 847 5700 |
| Web | https://www.taro.com |
Taro Pharmaceutical Management Efficiency
Taro Pharmaceutical's management efficiency ratios could be used to measure how well Taro Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Taro Pharmaceutical Industries currently holds 369.06 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Taro Pharmaceutical has a current ratio of 3.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Taro Pharmaceutical's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 13 records | CEO Age | ||
| Paul Josephs | Lifecore Biomedical | 59 | |
| Gary Sr | Organogenesis Holdings | 70 | |
| Venkata MBA | Dr Reddys Laboratories | 56 | |
| Mario DPHIL | Evotec SE ADR | 61 | |
| Frank Lee | Pacira BioSciences, | 57 | |
| Jack Khattar | Supernus Pharmaceuticals | 63 | |
| Milan Kalawadia | Dr Reddys Laboratories | N/A | |
| Nikhil Lalwani | ANI Pharmaceuticals | 46 | |
| James Hall | Lifecore Biomedical | 62 | |
| M Ramana | Dr Reddys Laboratories | 52 | |
| Vikram Karnani | Collegium Pharmaceutical | 50 | |
| Patrick Aghanian | Dr Reddys Laboratories | 55 | |
| MARC KIKUCHI | Dr Reddys Laboratories | 51 | |
Management Performance
| Return On Equity | 0.0306 | |||
| Return On Asset | 0.0021 |
Taro Pharmaceutical Leadership Team
Elected by the shareholders, the Taro Pharmaceutical's board of directors comprises two types of representatives: Taro Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Taro. The board's role is to monitor Taro Pharmaceutical's management team and ensure that shareholders' interests are well served. Taro Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Taro Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erik Zwicker, Vice President General Counsel, Secretary | ||
| Abhay Gandhi, Vice Chairman of the Board | ||
| Avi Avramoff, Global Vice President - Research & Development | ||
| Chantal LeBlanc, Vice President - Head of Quality | ||
| Robert Stein, Independent Director | ||
| Erik JD, General VP | ||
| Jayesh Shah, Head of Procurement | ||
| Itamar Karsenti, Vice President - Head of Operations, Haifa | ||
| James Kedrowski, Director | ||
| Sudhir Valia, Director | ||
| Uday Baldota, Chief Executive Officer, Director | ||
| Dilip Shanghvi, Chairman of the Board | ||
| Richard Glaze, Vice President - Head of Information Technology | ||
| Roman Kaplan, Vice Manager | ||
| William Coote, Vice President Treasurer | ||
| Ori Gutwerg, Vice President - Head of US Generics Rx | ||
| Vikash Agarwal, Vice President - Head of Business Development | ||
| Linda Benshoshan, Independent Director | ||
| Michele Visosky, Vice President - Head of Human Resources | ||
| Ara Aprahamian, Vice President - Sales and Marketing | ||
| Itzik Baruch, Vice Services | ||
| Daphne Huang, Chief Financial Officer, Chief Accounting Officer, Vice President | ||
| Victoria Chester, Vice President - Head of Quality | ||
| Dov Pekelman, Independent Director |
Taro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Taro Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0306 | |||
| Return On Asset | 0.0021 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 735.67 M | |||
| Shares Outstanding | 37.58 M | |||
| Shares Owned By Insiders | 78.48 % | |||
| Shares Owned By Institutions | 13.06 % | |||
| Number Of Shares Shorted | 73.56 K | |||
| Price To Earning | 14.57 X |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Taro Stock
If you are still planning to invest in Taro Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taro Pharmaceutical's history and understand the potential risks before investing.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Stocks Directory Find actively traded stocks across global markets |